These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37200480)

  • 1. Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature.
    Martin-García C; Godoy E; Cabrera A; Cañueto J; Muñoz-Bellido FJ; Perez-Pazos J; Dávila I
    Int J Immunopathol Pharmacol; 2023; 37():3946320231172881. PubMed ID: 37200480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation.
    Yan S; Wu X; Jiang J; Yu S; Fang X; Yang H; Bai X; Wang H; Luo X
    Front Immunol; 2022; 13():1054422. PubMed ID: 36569942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab Therapy for Netherton Syndrome.
    Luchsinger I; Knöpfel N; Theiler M; Bonnet des Claustres M; Barbieux C; Schwieger-Briel A; Brunner C; Donghi D; Buettcher M; Meier-Schiesser B; Hovnanian A; Weibel L
    JAMA Dermatol; 2020 Aug; 156(8):907-911. PubMed ID: 32459284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term dupilumab therapy in Netherton syndrome with severe atopic manifestations: Case report and review of the literature.
    Özkaya E; Günay MB; Babuna Kobaner G; Keskinkaya Z; Gökalp MO
    Australas J Dermatol; 2023 May; 64(2):272-277. PubMed ID: 36745433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.
    Tsianakas A; Luger TA; Radin A
    Br J Dermatol; 2018 Feb; 178(2):406-414. PubMed ID: 28845523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.
    Chan S; Cornelius V; Cro S; Harper JI; Lack G
    JAMA Pediatr; 2020 Jan; 174(1):29-37. PubMed ID: 31764962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab use in the treatment of Netherton's syndrome.
    Gan C; King E; Orchard D
    Australas J Dermatol; 2022 Aug; 63(3):365-367. PubMed ID: 35622930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study.
    Ureña-Paniego C; Montero-Vílchez T; Sanabria-de-la-Torre R; Soto-Moreno A; Molina-Leyva A; Arias-Santiago S
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease.
    Spencer EA; Dolinger MT; Dubinsky MC
    Dig Dis Sci; 2023 Apr; 68(4):1121-1124. PubMed ID: 36064828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series.
    Ragamin A; Nouwen AEM; Dalm VASH; van Mierlo MMF; Lincke CR; Pasmans SGMA
    Dermatology; 2023; 239(1):72-80. PubMed ID: 35998563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
    Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
    J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels.
    Yalcin AD
    Immunopharmacol Immunotoxicol; 2016; 38(2):162-6. PubMed ID: 26592187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome.
    Murase C; Takeichi T; Taki T; Yoshikawa T; Suzuki A; Ogi T; Suga Y; Akiyama M
    J Dermatol Sci; 2021 May; 102(2):126-129. PubMed ID: 33773888
    [No Abstract]   [Full Text] [Related]  

  • 19. Netherton syndrome in a Bulgarian patient : Presentation of a case and an update of therapeutic options.
    Kordeva SA; Batashki I; Tchernev G
    Wien Med Wochenschr; 2023 Sep; 173(11-12):276-286. PubMed ID: 36695942
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.